Jeff Bank is a partner in Wilson Sonsini Goodrich & Rosati's New York office, where he practices antitrust litigation and counseling, particularly in the pharmaceutical industry.

As an experienced litigator representing both plaintiffs and defendants, Jeff's work has ranged from complex multi-district litigations and global cartel cases to actions against competitors. He has successfully defended pharmaceutical, technology, and media companies against class actions, and has experience in all aspects of litigation, from discovery through appeal.

Prior to joining the firm, Jeff practiced at the Federal Trade Commission's Health Care Division, where he focused on competition issues in the pharmaceutical and healthcare industry. In his current practice, he regularly counsels clients on merger clearance issues and business practices, and he has represented a diverse range of clients before the FTC, including companies from the medical device, pharmaceutical, and media sectors.

Jeff also serves as the pro bono coordinator for the New York office, and he has worked on numerous immigration and asylum-related matters. He was awarded the John Wilson Award, which is presented annually to individual attorneys who have demonstrated a significant commitment to the firm's pro bono clients. Additionally, Jeff currently serves as board president for Spoons Across America, a New York-based nonprofit.

  • J.D., Cornell University Law School, 2006
    Editor, International Law Journal
  • B.S., Cornell University, School of Industrial and Labor Relations, 2003
  • Co-author with M. Rosman and B. Tuyay, "Retaining Ephemeral Messages To Prepare For DOJ Scrutiny," Law360, July 29, 2019
  • Co-author with C. Boylu and B. Coffman, "The Latest Developments in Antitrust Class Certification," Law360, January 30, 2019
  • "U.S.A." chapter, Competition Litigation 2018, Tenth Edition, International Comparative Legal Guide, September 4, 2017
  • "U.S.A." chapter, Competition Litigation 2017, Ninth Edition, International Comparative Legal Guide, September 16, 2016
  • Co-author with S. Silber and B. Coffman, "A Return to Republican Antitrust Policies for Pharma," Law360, January 24, 2017
  • Co-author with S. Silber, C. Armour, K. Kemp, B. Coffman, and R. Maddock, "Pharmaceutical Antitrust Litigation in 2015—Settlements, Product Hopping and REMS," CPI Antitrust Chronicle, Competition Policy International, December 14, 2015
  • Co-author with S. Silber, B. Coffman, and K. Kemp, "Where We Stand On Pharmaceutical Patent Settlements," Law360, October 23, 2015
  • "U.S.A." chapter, Competition Litigation 2016, Eighth Edition, International Comparative Legal Guide, September 25, 2015
  • Co-author with M. Rosman, S. Silber, J. VanHooreweghe, and B. Coffman, "DOJ Investigation into Generic Pharma: You Could Be Next," Law360, March 30, 2015
  • Presenter, "Recent Developments in Private Litigation," ABA Corporate Counseling Committee Monthly Antitrust Update, Section of Antitrust Law, February 2019
  • "All Things Vertical: Divergence or Convergence?" Fordham Competition Law Institute 45th Annual Conference on International Antitrust Law and Policy, September 2018
  • "REMS: Are the Federal Agencies Signaling Increased Scrutiny?" American Bar Association Health Care and Pharmaceuticals Committee Panel, June 2018
  • "End the Shenanigans or Business as Usual?: Update on Pharmaceutical Antitrust Issues," New York City Bar Association Antitrust & Trade Regulation Committee, November 2017
  • "Pushing Forward or Staying the Course?: Product Hopping, Exclusionary Conduct, and the Recent Suboxone MTD Ruling," American Bar Association State Enforcement Committee Panel, October 2017
  • State Bar of New York
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • U.S. Court of Appeals for the First Circuit
  • U.S. Court of Appeals for the Ninth Circuit